Personalis News | finanzen.ch

Personalis Aktie VALOR 48180521 / ISIN US71535D1063

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

19.12.24	Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna (Businesswire)
16.12.24	Personalis and Tempus Expand Collaboration to Biopharma (Businesswire)
16.09.24	ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test (Businesswire)
19.08.24	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
04.06.24	ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring (Businesswire)
31.05.24	Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus (Businesswire)
22.05.24	Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 (Businesswire)
17.05.24	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.03.24	Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (Businesswire)
26.03.24	Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring (Businesswire)
19.03.24	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.02.24	Personalis Reports Fourth Quarter and Full Year 2023 Financial Results (Businesswire)
14.02.24	Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results (Businesswire)
30.01.24	Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology (Businesswire)
17.01.24	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
16.01.24	Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay (Businesswire)
05.01.24	Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance (Businesswire)
04.12.23	Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives (Businesswire)
28.11.23	Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing (Businesswire)
26.10.23	Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer (Businesswire)
21.10.23	Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology (Businesswire)
19.10.23	Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023 (Businesswire)
18.10.23	Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	56.62	1.65 %	K V
Logitech Intl	86.28	0.84 %	K V
Holcim	67.40	0.48 %	K V
Part Grp Hldg	1’063.00	0.38 %	K V
CieFinRichemont	148.35	0.37 %	K V
Novartis	100.74	-1.29 %	K V
Roche Hldg G	266.10	-1.33 %	K V
Lonza Grp	556.60	-2.08 %	K V
Givaudan	3’405.00	-3.51 %	K V